Where We Agree When It Comes to Regulating Laboratory-Developed Diagnostics.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 9, p. 387
- By:
- Publication type:
- Article
Works matching IS 21660166 AND DT 2016 AND VI 5 AND IP 9
Results: 12
1
2
Managing Immune-Related Toxicities.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 9, p. 385
- Publication type:
- Article
3
Pembrolizumab plus Chemotherapy Doubled Response Rate Over Chemotherapy Alone in NSCLC.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 9, p. 384
- Publication type:
- Article
4
Practice-Changing Study Shows Niraparib Extends Progression-Free Survival in Platinum-Sensitive Ovarian Cancer.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 9, p. 383
- Publication type:
- Article
5
Encouraging Outcome with Adjuvant Sunitinib in Renal Cell Carcinoma.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 9, p. 382
- Publication type:
- Article
6
Potentially Practice-Changing: Ribociclib/Letrozole Combo in Advanced Breast Cancer.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 9, p. 381
- Publication type:
- Article
7
Quality of Life Improved with Nivolumab versus Chemotherapy.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 9, p. 380
- Publication type:
- Article
8
Published Studies Underreport Toxicities Associated with Targeted Therapy and Immunotherapy.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 9, p. 379
- Publication type:
- Article
9
A One Pathway "Two-Different Hit" Hypothesis: Symbiosis in Transformation.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 9, p. 376
- By:
- Publication type:
- Article
10
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 9, p. 370
- By:
- Publication type:
- Article
11
Understanding the Current Classification Criterion and Prognostic Models for the Myelodysplastic Syndromes and Dysplastic Cytopenias of Undetermined Significance as a Paradigm for Personalized Medicine.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 9, p. 361
- By:
- Publication type:
- Article
12
Providing Practical Information to Promote Targeted, Effective, and Personalized Treatments.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 9, p. 360
- By:
- Publication type:
- Article